iRadimed Corporation (NASDAQ:IRMD – Get Free Report) CEO Roger Susi sold 3,089 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $84.54, for a total transaction of $261,144.06. Following the completion of the transaction, the chief executive officer owned 2,184,411 shares in the company, valued at approximately $184,670,105.94. This trade represents a 0.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Stock Up 0.6%
Shares of IRMD stock traded up $0.52 during trading on Wednesday, hitting $85.27. The company had a trading volume of 71,131 shares, compared to its average volume of 86,931. The stock’s 50-day moving average is $94.77 and its two-hundred day moving average is $94.62. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of 46.60 and a beta of 0.90. iRadimed Corporation has a 52 week low of $50.88 and a 52 week high of $107.90.
iRadimed (NASDAQ:IRMD – Get Free Report) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. The company had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, research analysts predict that iRadimed Corporation will post 1.52 EPS for the current fiscal year.
iRadimed Announces Dividend
Wall Street Analysts Forecast Growth
Several analysts have issued reports on IRMD shares. Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Weiss Ratings raised iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 6th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $120.00.
Read Our Latest Research Report on iRadimed
Institutional Trading of iRadimed
Several hedge funds and other institutional investors have recently bought and sold shares of IRMD. T. Rowe Price Investment Management Inc. boosted its stake in iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after buying an additional 205,783 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in iRadimed by 37.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after buying an additional 55,426 shares in the last quarter. Informed Momentum Co LLC purchased a new stake in shares of iRadimed during the fourth quarter valued at approximately $5,361,000. SG Americas Securities LLC boosted its stake in shares of iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after purchasing an additional 33,072 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of iRadimed by 473.9% during the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after purchasing an additional 29,010 shares during the period. Hedge funds and other institutional investors own 92.34% of the company’s stock.
About iRadimed
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Read More
- Five stocks we like better than iRadimed
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
